“The current circumstance has exposed some structural weaknesses from the EU’s medicines source chain and also a large dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides mentioned. She suggested that supply chain concerns be tackled in an EU pharmaceutical tactic predicted to become introduced by t